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Abstract
Necroptosis is a regulated caspase-independent cell death pathway with morphological features
resembling passive non-regulated necrosis. Several diverse structure classes of necroptosis
inhibitors have been reported to date, including a series of 3,3a,4,5-tetrahydro-2H-
benz[g]indazoles (referred to as the Nec-3 series) displaying potent activity in cellular assays.
However, evaluation of the tricyclic necroptosis inhibitor’s stability in mouse liver microsomes
indicated that they were rapidly degraded. A structure-activity relationship (SAR) study of this
compound series revealed that increased liver microsomal stability could be accomplished by
modification of the pendent phenyl ring and by introduction of a hydrophilic substituent (i.e. α-
hydroxyl) to the acetamide at the 2-position of the tricyclic ring without significantly
compromising necroptosis inhibitory activity. Further increases in microsomal stability could be
achieved by utilizing the 5,5-dioxo-3-phenyl-2,3,3a,4-tetrahydro-[1]benzothiopyrano[4,3-
c]pyrazoles. However, in this case necroptosis inhibitory activity was not maintained. Overall,
these results provide a strategy for generating potent and metabolically stable tricyclic necrostatin
analogs (e.g. 33, LDN-193191) potentially suitable for in vivo studies.
Necroptosis is a regulated caspase-independent cell death pathway with morphological
features resembling passive non-regulated necrosis.1, 2 This type of cell death can be
© 2012 Elsevier Ltd. All rights reserved.
*To whom correspondence should be addressed: Phone: +1-713-743-1274, Fax: +1-713-743-1884, gdcuny@central.uh.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 September 01.
Published in final edited form as:
Bioorg Med Chem Lett. 2012 September 1; 22(17): 5685–5688. doi:10.1016/j.bmcl.2012.06.098.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
initiated with various stimuli (e.g. TNF-α and Fas ligand) and in a variety of cell types (e.g.
monocytes, fibroblasts, lymphocytes, macrophages, epithelial cells and neurons).
Furthermore, necroptosis may represent a significant contributor to and in some cases
predominant mode of cellular demise under pathological conditions involving excessive cell
stress, rapid energy loss and massive oxidative species generation, not conducive for highly
energy-dependent processes, such as apoptosis. Regulated necrotic cell death mechanisms,
such as necroptosis, raises the possibility of novel therapeutic intervention strategies for the
treatment of conditions where necrosis is known to play a prominent role, such as organ
ischemia (i.e. stroke3 and myocardial infarction4), trauma and possibly some forms of
neurodegeneration.5
To date several diverse structure classes of necroptosis inhibitors have been reported,
including hydantoin containing indole derivatives (i.e. 1),6 rel-(3R,3aR)-3-phenyl-3,3a,4,5-
tetrahydro-2H-benz[g]indazoles (i.e. 2),7 substituted 3H-thieno[2,3-d]pyrimidin-4-ones (i.e.
3),8 [1,2,3]thiadiazole benzylamides (i.e. 4)9 and pyrrole benzylamides (i.e. 5)10 (Figure 1).
Many of these compounds block necroptosis through inhibition of receptor interacting
protein 1 (RIP1) kinase.11 In addition, (±)-1 has demonstrated in vivo activity in the
temporary and permanent middle cerebral artery occlusion (MCAO) model of cerebral
ischemia1, in a mouse model of ischemia/reperfusion heart injury,12 in the controlled
cortical impact (CCI) model of traumatic brain injury (TBI),13 a retinal ischemia-reperfusion
injury model,14 a systemic inflammatory response syndrome (SIRS) model,15 and a
Huntington’s disease model.16
In order to evaluate the in vivo pharmacology of other necroptosis inhibitors via preferred
administration routes (i.e. oral, intravenous, intraperitoneal or subcutaneous) they must
possess adequate metabolic stability, in addition to in vitro potency. One efficient and cost
effective method of assessing a compound’s metabolic stability is to measure its resistance
to metabolism over time in the presence of liver microsomes.17 Utilizing this technique with
mouse liver microsomes, compound 2, which inhibits necroptosis induced with TNF-α in
FADD-deficient variant of human Jurkat T cells with an EC50 value of 0.29 μM,
demonstrated poor metabolic stability with a half-life (t1/2) of 8.2 min and intrinsic clearance
(CLint) of 169 ± 2.0 μL/min/mg protein. Herein, we describe the results of a SAR study to
optimize the in vitro liver microsomal stability of the tricyclic (Nec-3) class of necroptosis
inhibitors.
Many of the tricyclic derivatives evaluated herein were prepared according to the procedure
outlined in Scheme 1.7 1-Tetralones, 4-chromanones and 4-thiochromanones, 6, were treated
with benzaldehydes or phenylacetaldehyde under basic or acid conditions to give 7. The
chalcones were allowed to react with hydrazine hydrate utilizing various acids (R3CO2H) as
solvent to give a mixture of two diastereomers, the (3R,3aR)-rel-isomers 8a – 11a and the
(3R,3aS)-rel-isomers 8b – 11b. The diastereomers were readily separated by column
chromatography on silica gel and the stereochemical assignments were made using 1H-
NMR. Removal of the benzyl group in 9a was accomplished by hydrogenation in the
presence of 10% Pd/C to give alcohol 12. Oxidation of 10a and 11a with m-
chloroperoxybenzoic acid (m-CPBA) gave sulfones 13 and 14, respectively. Sulfone 14 was
subsequently converted to alcohol 15 by hydrogenation.
Derivatives containing a methyl group at the 3a-position were prepared according to the
procedure outlined in Scheme 2. Initial attempts to prepare these derivatives from an α-
methyl-1-tetralone derivative utilizing the same synthetic strategy employed for the
preparation of the 3a-H derivatives were unsuccessful. Instead, 7-methoxy-1-tetralone, 16,
was deprotonated with NaN(TMS)2 and then allowed to react with 4-methyoxybenzoyl
chloride to give the 1,3-diketone 17. This compound was again subjected to the same
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process, except that the anion was quenched with iodomethane to give 1,3-diketone 18.
Condensation of 18 with hydrazine hydrate in the presence of 4Å molecular sieves gave
19.18 Treatment of 19 at −78 °C with acetyl chloride followed by reduction of the in situ
generated acyl iminium gave a mixture of diastereomers 20a and 20b in a ratio of 1:1.7,
favoring isomer 20b where the hydride anion approaches the acyl iminium intermediate
distal to the 3a-Me. The 3a-Me of 20b, which is syn to the pendent phenyl, was shielded and
appeared at δ 0.69 in the 1H NMR spectra.19a The 3a-Me of 20a appeared further downfield
at δ 1.59.19b The structure of 20b was confirmed by single crystal x-ray analysis and
reaffirmed the regioselectivity of the acylation reaction and the stereochemical assignments
of the diastereomers (Figure 2).20
In vitro microsomal stability was determined in pooled mouse liver microsomes. Test
compounds (Table 1) were incubated in the presence and absence of NADPH for 0 – 60 min
and the amount of remaining compound was quantified.21 Necroptosis inhibitor (±)-1
demonstrated good metabolic stability in this assay with a t1/2 = 59.1 min and CLint = 23.5 ±
2.1 μL/min/mg protein. Evaluation of necroptosis inhibitory activity was performed using a
FADD-deficient variant of human Jurkat T cells treated with TNF-α as previously
described.1, 7 Utilizing these conditions the cells efficiently underwent necroptosis, which
was completely and selectively inhibited by (±)-1 (EC50 = 0.21 μM). For EC50 value
determinations, cells were treated with 10 ng/mL of human TNF-α in the presence of
increasing concentration of test compounds (eleven doses between 30 nM to 100 μM) for 24
h followed by ATP-based viability assessment.
Several regions of the tricyclic necroptosis inhibitor 2 were considered potential liability
sites responsible for the compound’s poor metabolic stability in mouse liver microsomes.
These sites included the methoxy groups at both the 8-position of the tricyclic ring and the
4-position of the pendent phenyl, the dihydropyrazole ring, the benzylic carbon at the 5-
positions and the amide at the 2-position.
Introduction of a methyl group at the 3a-position of the tricyclic ring (20a and 20b), which
was envisioned to block potential oxidation of the dihydropyrazole, did not result in
improved stability. Interestingly, necroptosis inhibitory actively was dramatically decreased
for both diastereomers. Replacement of the benzylic methylene at the 5-position with
oxygen (22) did not result in an increase in metabolic stability. When the methoxy group at
the 8-position of the tricyclic ring was further replaced with a fluorine (23) metabolic
stability remained poor. Substitution of the benzylic methylene with sulfur (24) similarly did
not improve stability. However, replacement with a sulfone (25) did result in a significant
increase in metabolic stability (t1/2 = 40 min and CLint = 34.6 ± 2.6 μL/min/mg protein)
with a slight decrease in necroptosis inhibitory activity. Introduction of a methylene group
between the 3-position of the tricyclic ring and the pendent phenyl ring (26) similarly did
not increase stability, but did eliminate necroptosis inhibitory activity. Addition of a
hydroxyl group on the α-position of the amide (27 vs. 2 and 28 vs. 29) or introduction of a
trifluoromethoxy in place of a methoxy at the 4-position of the pendent phenyl ring (30 vs.
2) resulted in increased metabolic stability. A combination of these changes (31) yielded a
further increase in stability (t1/2 = 54 min and CLint = 25.5 ± 3.8 μL/min/mg protein). A
similar result was also found with a sulfone derivative (25 vs. 32), albeit necroptosis
inhibitory activity was compromised. Although introduction of fluorine at the 3-position of
the pendent phenyl ring did not increase stability in one case (2 vs. 28), in another instance
this change in combination with a hydroxyl group on the α-position of the amide and a
trifluoromethoxy at the 4-position of the pendent phenyl (2 vs. 33) resulted in a significant
(18-times) stability increase (t1/2 = 148 min and CLint = 9.38 ± 1.4 μL/min/mg protein) with
only a modest (2-fold) decrease in necroptosis inhibitory activity.
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In conclusion, increased liver microsomal stability as well as improvement in activity were
accomplished for the tricyclic (Nec-3) series of necroptosis inhibitors by modification of the
pendent phenyl and by introduction of a hydrophilic substituent (i.e. α-hydroxyl) to the
acetamide at the 2-position, resulting in inhibitor 33 (LDN-193191).19c The benzylic
position of the tricyclic ring also appeared to influence metabolic stability. Although
replacement of the methylene group with a sulfone increased metabolic stability, it
significantly decreased necroptosis inhibitory activity. Additional optimization of tricyclic
necroptosis inhibitors utilizing the information from this study may result in further
increases in metabolic stability and provide a unique set of necroptosis inhibitors suitable for
in vivo analysis of the pathologic role of necroptosis following acute and potentially chronic
injury.
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Figure 1.
Necrostatins. The numbering convention of 2 is also shown.
Choi et al. Page 6
Bioorg Med Chem Lett. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Thermal ellipsoidal drawing of 20b as determined by single crystal x-ray analysis.
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Scheme 1.
(a) Ar(CH2)nCHO, 8N NaOH, EtOH, rt, 2 h or Ar(CH2)nCHO, conc HCl, MeOH, Δ, 4 h (60
– 75%); (b) R3CO2H, NH2NH2·xH2O, 120 °C, 15 h (70 – 80% when n = 0; 20% when n =
1); (c) H2 (1 atm), 10% Pd/C, EtOH (47–75%); (d) MCPBA, DCM, rt, 16 h (90–96%).
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Scheme 2.
(a) NaN(TMS)2, THF, 0 °C, then 4-MeO-PhC(O)Cl, 0 °C to rt (80%); (b) NaN(TMS)2,
THF, 0 °C, then MeI, 0 °C to rt (91%); (c) NH2NH2·xH2O, DCM, 4Å molecular sieves
(52%); (d) MeC(O)Cl, DCM, −78 °C, then NaBH(OAc)3, −78 °C to rt (95%).
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Table 2
EC50 determinations for necroptosis inhibition in FADD-deficient Jurkat T cells treated with TNF-α and
mouse microsomal stability values.
Compound EC50 (μM)a t1/2 (min) CLint (μL/min/mg protein)
2 0.29 8.2 169 ± 2.0
20a > 100 2.9 476 ± 53.9
20b 15 7.2 194 ± 5.9
21 0.39 15 90.7 ±13.4
22 0.46 10 135 ± 9.3
23 12 11 120 ± 39.3
24 0.28 12 115 ± 18.5
25 0.75 40 34.6 ± 2.6
26 > 100 3.0 463 ± 78.1
27 0.16 33 42.4 ± 5.5
28 0.090 8.6 162 ± 5.7
29 0.28 27 50.5 ± 3.6
30 0.33 20 68.7 ± 18.0
31 0.64 54 25.5 ± 3.8
32 27 115 12.1 ± 1.4
33 0.61 148 9.38 ± 1.4
aStandard deviation < 10%.
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